

Market Announcement

28 September 2018

Bionomics Limited (ASX: BNO) – Trading Halt

Description

The securities of Bionomics Limited ('BNO') will be placed in trading halt at the request of BNO, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 2 October 2018 or when the announcement is released to the market.

Issued by

Rupa Kapadia

Adviser, Listings Compliance (Sydney)

28 September 2018

Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney NSW 2000

Attention: Ms Rupa Kapadia Adviser, Listings Compliance

Dear Ms Kapadia,

Request for Trading Halt

Pursuant to Listing Rule 17.1, Bionomics Limited (ASX: BNO) (OTCQX: BNOEF) requests a trading halt be granted by the Australian Securities Exchange with respect to its securities, commencing from the start of trading today.

The trading halt is requested to prevent trading of the Company's securities in an uninformed market and assist the Company to manage its continuous disclosure obligations pending an announcement regarding the results of its BNC210 Phase 2 clinical trial in patients with Post Traumatic Stress Disorder.


Bionomics requests that the trading halt operates until an announcement is made or the commencement of trading on Tuesday 2 October 2018, whichever occurs first.

Bionomics is not aware of any reason why the trading halt should not be granted.

Bionomics is not aware of any other information about which the market should be informed in relation to the trading halt.

Please do not hesitate to contact me if you have any queries.

Yours faithfully,



Jack Moschakis
Legal Counsel & Company Secretary